Anticholinergic medications in community-dwelling older veterans: Prevalence of anticholinergic symptoms, symptom burden, and adverse drug events

doi:10.1016/j.amjopharm.2006.03.008

The American Journal of Geriatric Pharmacotherapy

Volume 4, Issue 1, March 2006, Pages 42-51

https://doi.org/10.1016/j.amjopharm.2006.03.008 Get rights and content

Abstract

Background:

The use of drugs with anticholinergic adverse effects is often deemed inappropriate in elderly (aged ≥65 years) patients, yet studies continue to show extensive use in this population at high risk for adverse drug events (ADEs). The burden of drug-related anticholinergic symptoms in community-dwelling elderly patients has not been well described.

Objective:

The aim of this study was to assess the prevalence of anticholinergic symptoms, corresponding symptom burden, and anticholinergic-related ADEs in a sample of community-dwelling elderly veterans.

Methods:

This prospective cohort study was conducted at the primary care clinics at the Veterans Affairs Medical Center (VAMC), Iowa City, Iowa. The study sample included randomly selected patients with intact cognitive function attending the VAMC and prescribed ≥5 scheduled medications. Data on current prescription and nonprescription drug use were elicited by a trained research assistant and a clinical pharmacist from patient interviews and electronic medical records. The prevalence and severity of 7 anticholinergic symptoms (dry mouth, constipation, blurred vision, confusion, urinary hesitation, dry eyes, and drowsiness) were assessed at baseline. The occurrence of ADEs at 12 weeks was compared between patients using anticholinergic drugs and those not using them.

Results:

A total of 532 patients were included (97.9% men; mean age, 74.3 years; 27.1% used at least 1 anticholinergic drug). Twenty-two anticholinergic drugs (16 prescription medications, 6 over-the-counter medications) were identified. The mean number of anticholinergic symptoms was significantly higher in the group using anticholinergic drugs (3.1 vs 2.5; P < 0.01). However, only 2 symptoms were statistically more prevalent in the group using anticholinergic drugs: dry mouth (57.6% vs 45.6%) and constipation (42.4% vs 29.4%) (both, P < 0.01). At 12 weeks, only 1 (0.8%) patient in the group using anticholinergic drugs reported an ADE considered related to an anticholinergic drug.

Conclusions:

Anticholinergic drug use was common (27.1%) in these elderly veterans with intact cognitive function. The mean number of anticholinergic symptoms was significantly greater in this group, and the prevalences of dry mouth and constipation were significantly higher in the group using anticholinergic drugs (all, P < 0.01). Anticholinergic-related ADEs were rare (0.8%). Although anticholinergic drugs should generally be avoided in the elderly, individual risks and benefits for a patient should be considered.

References (25)

BasuR. et al.
Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: Effects on cognition
Am J Geriatr Psychiatry
(2003)
FlackerJ.M. et al.
The association of serum anticholinergic activity with delirium in elderly medical patients
Am J Geriatr Psychiatry
(1998)
LuC.J. et al.
Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease
Am J Geriatr Psychiatry
(2003)
PortenoyR.K. et al.
The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress
Eur J Cancer
(1994)
FickD.M. et al.
Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts
Arch Intern Med
(2003)
HanlonJ.T. et al.
Inappropriate drug use among community-dwelling elderly
Pharmacotherapy
(2000)
CurtisL.H. et al.
Inappropriate prescribing for elderly Americans in a large outpatient population
Arch Intern Med
(2004)
TuneL.E.
Anticholinergic effects of medication in elderly patients
J Clin Psychiatry
(2001)
MooreA.R. et al.
Drug-induced cognitive impairment in the elderly
Drugs Aging
(1999)
Lechevallier-MichelN. et al.
Frequency and risk factors of potentially inappropriate medication use in a community-dwelling elderly population: Results from the 3C Study
Eur J Clin Pharmacol
(2005)

RuddK.M. et al.

Methods for assessing drug-related anticholinergic activity

Pharmacotherapy

(2005)

MulsantB.H. et al.

Serum anti-cholinergic activity in a community-based sample of older adults: Relationship with cognitive performance

Arch Gen Psychiatry

(2003)

Cited by (134)

Home medication inventory method to assess over-the-counter (OTC) medication possession and use: A pilot study on the feasibility of in-person and remote modalities with older adults
2024, Research in Social and Administrative Pharmacy
There is a need for reproducible methods to measure over-the-counter (OTC) medication possession and use. This is because OTC medications are self-managed, variably monitored by healthcare professionals, and in certain populations such as older adults some OTC medications may introduce risk and cause more harm than benefit.
(s): To develop and assess the feasibility of the Home Medication Inventory Method (HMIM), a novel method to measure possession and use of OTC medications.
We benchmarked, adapted, and standardized prior approaches to medication inventory to develop a method capable of addressing the limitations of existing methods. We then conducted a pilot study of the HMIM among older adults. Eligible participants were aged ≥60 years, reported purchasing or considering purchasing OTC medication, and screened for normal cognition. Interviews were conducted both in person and remotely. When possible, photographs of all OTC medications were obtained with participant consent and completion times were recorded for both in-person and remote modalities.
In total 51 participants completed the pilot study. Home medication inventories were conducted in-person (n = 15) and remotely (n = 36). Inventories were completed in a mean (SD) of 20.2 min (12.7), and 96 % of inventories completed within 45 min. A total of 390 OTC medications were possessed by participants, for a mean (SD) of 7.6 (6.3) per participant. No differences in duration of interviews or number of medications reported were identified between in-person and remote modalities. Anticholinergic medications, a class targeted in the pilot as potentially harmful to older adults, were possessed by 31 % of participants, and 14 % of all participants reported use of such a medication within the previous 2 weeks.
Implementing the HMIM using in-person and remote modalities is a feasible and ostensibly reproducible method for collecting OTC medication possession and use information. Larger studies are necessary to further generalize HMIM feasibility and reliability in diverse populations.
Risk factors for hospital-acquired pneumonia among inpatients with mental disorders in a large mental health center within a tertiary general hospital
2023, American Journal of Infection Control
Few researchers have investigated the incidence of and risk factors for hospital-acquired pneumonia (HAP) among inpatients with mental disorders in a general hospital.
This study included patients with mental disorders hospitalized in a large mental health center (situated in a general hospital) between January 1, 2017, and July 31, 2021 (excluding January 1, 2020- May 31, 2020). Risk factors for HAP were identified by logistic regression analysis after propensity score matching (PSM, 1:4) for gender, age, duration of observation, and hospital ward.
The study included 16,864 patients. HAP incidence rate was 1.15% overall, 2.11% in closed wards, 0.75% in open wards, 4.45% in patients with organic mental disorders, 1.80% in patients with schizophrenia spectrum disorders, and 0.84% in patients with mood disorders. Risk factors for HAP after PSM were hypoproteinemia, chronic liver disease, use of clozapine, hospitalization during the previous 180 days, body mass index (BMI) ≤18.5 kg/m², cholinesterase inhibitor use, and mood stabilizer use.
HAP was common among inpatients with mental disorders. Risk factors for HAP in patients with mental disorders include hypoproteinemia, chronic liver disease, hospitalization during the past 180 days, BMI ≤18.5 kg/m², and use of clozapine, cholinesterase inhibitors, or mood stabilizers.
Anticholinergic medication and dental caries status in middle-aged xerostomia patients-a retrospective study
2022, Journal of Dental Sciences
Xerostomia is the most frequent side effect of anticholinergic (AC) medications, which block the cholinergic neurotransmission of saliva secretion. As the most significant increase in AC medications’ usage reported in middle-aged adults, we aimed to explore whether the level of exposure to AC medication show association with the severity of caries status of middle-aged individuals who complained about medication-induced xerostomia.
Our retrospective study included 414 individuals (between 45 and 64 years) with self-reported xerostomia. We determined caries status by the Decayed, Missing, or Filled Teeth (DMFT) index and quantified the level of AC drug exposure by the AC Drug Scale (ADS), verified through electronic medication records. Statistical analyses were performed using chi-square and ANOVA tests. Covariates were age, gender, smoking, edentulism, comorbidities, polypharmacy, number, and the type of AC medications.
In total, 54% of patients were taking five or more AC drugs. The mean number of anticholinergics was 5.41 (±3.44), most frequently antidepressants and antipsychotics, among all medications 10.63 (±5.79). Higher ADS scores were associated (p = 0.006) with a higher number of missing teeth. Multiple linear regression model showed that the number of AC medications, age, and smoking status are associated with DMFT (mean of 18.7 ± 8.96) scores.
Caries status of middle-aged xerostomia patients was found to be reflective of the level of AC exposure from medications. Our finding emphasizes the importance of assessing AC medication burden in affected dental patients to improve clinical prevention strategies and guide interdisciplinary treatment plans.
Anticholinergic medication: Related dry mouth and effects on the salivary glands
2021, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Citation Excerpt :
The AC burden has been used to estimate the risk of dementia and mortality in older adults.38 Few dental studies6,39 have investigated the salivary secretion in relation to the AC burden14 and established a positive correlation between AC burden (measured by ADS) and dry mouth.40,41 The ADS, compiled by Carnahan et al.37 and Duran et al.,42 includes over 100 commonly prescribed muscarinic receptor antagonists27 according to their antimuscarinic activity on muscarinic receptors.
Salivary glands are among the most sensitive target organs of medications with anticholinergic (AC) properties, interrupting the neural stimulation of saliva secretion and reducing saliva flow. Hyposalivation results in dry mouth, leading to dental caries, intraoral infection, orofacial pain, problems with speaking and swallowing, and diminished oral health--related quality of life. Current understanding of the pharmacokinetics of AC medications and their effect on muscarinic receptors in the salivary glands were reviewed to assist clinicians in predicting salivary damage in patients with AC medication–induced dry mouth.
We summarized the literature related to the mechanisms and properties of AC medications, anticholinergic adverse effects, and their effect on salivary function and management strategies to prevent oral health damage.
Although a large number of studies reported on the frequencies of medication-induced dry mouth, we found very limited data on predicting individual susceptibility to AC medication--caused hyposalivation and no prospective clinical studies addressing this issue.
Dry mouth is most frequently caused by medications with AC properties, which interrupt the neural stimulation of saliva secretion. Interdisciplinary care should guide pharmacotherapeutics and dental interventions should aim in preventing AC salivary adverse effects and reducing the oral health burden from AC medication–induced dry mouth.
The predictive value of anticholinergic drug exposure and the outcome of pneumonia: a Danish database study
2024, Age and Ageing
An Improved Statistical Modeling Approach to Individual Anticholinergic Drug Use Trend Analysis
2024, IEEE Journal of Biomedical and Health Informatics

View all citing articles on Scopus

View full text

Original researchAnticholinergic medications in community-dwelling older veterans: Prevalence of anticholinergic symptoms, symptom burden, and adverse drug events

Abstract

Background:

Objective:

Methods:

Results:

Conclusions:

Am J Geriatr Psychiatry

Am J Geriatr Psychiatry

Am J Geriatr Psychiatry

Eur J Cancer

Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts

Arch Intern Med

Inappropriate drug use among community-dwelling elderly

Pharmacotherapy

Inappropriate prescribing for elderly Americans in a large outpatient population

Arch Intern Med

Anticholinergic effects of medication in elderly patients

J Clin Psychiatry

Drug-induced cognitive impairment in the elderly

Drugs Aging

Frequency and risk factors of potentially inappropriate medication use in a community-dwelling elderly population: Results from the 3C Study

Eur J Clin Pharmacol

Methods for assessing drug-related anticholinergic activity

Pharmacotherapy

Serum anti-cholinergic activity in a community-based sample of older adults: Relationship with cognitive performance

Arch Gen Psychiatry

Original research
Anticholinergic medications in community-dwelling older veterans: Prevalence of anticholinergic symptoms, symptom burden, and adverse drug events